TB511

N/A

Report date: 2026/03/04 20:01:44
First In Class

Base Information

Drug NameTB511
Drug Alias NameTB511TB-511
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionMacrophages modulatorsIntegrin beta-2 binders
TargetsIntegrin beta-2
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTwinpig Biolab Inc
China Registration ClassN/A

Develop Information

Active CompaniesTwinpig Biolab Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A